Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJNBQA)

• DTT Name: Activin receptor-like kinase 2 (ALK-2) DTT Info
• Gene Name: ACVR1

Molecule-Related Drug & Molecule List

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INCB00928	DMFG8TI	Anemia	3A00-3A9Z	Phase 2	[1]
TP-0184	DMJVZBC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27774822-Compound-Figure10Compound12	DMFAGOZ	N. A.	N. A.	Patented	[3]
PMID27774822-Compound-Figure10Compound4	DMMJVTW	N. A.	N. A.	Patented	[3]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LDN-214117	DM57Z8J	Discovery agent	N.A.	Investigative	[4]
ML347	DMR8N36	Discovery agent	N.A.	Investigative	[5]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[5]
PMID23639540C13d	DMSTQGH	Discovery agent	N.A.	Investigative	[5]
PMID23639540C13r	DMHBZ0N	Discovery agent	N.A.	Investigative	[5]

References

• [1] Clinical pipeline report, company report or official report of Incyte.
• [2] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [3] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
• [4] Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
• [5] Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.